Moreover, increased uptake of endostatin by cholesterol-chelating agents such as nystatin or adding a macromolecule transduction domain (MTD) remarkably improves the therapeutic efficacy on tumor models (Chen et al., 2011; Lim et al., 2013). Here, COL18A1 is linked to neoplasm.